The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...
The funding round will enable the French startup to accelerate its expansion across Europe, expand its network of partner laboratories and physicians, and continue developing its platform.
John Johnson, current board member, appointed to chairman of the boardMichael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of developmentCommercial launch progresses as RAMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback